Literature DB >> 22037772

Lipid effects of antihypertensive medications.

Roderick Deano1, Matthew Sorrentino.   

Abstract

Thiazide diuretics and beta-blockers are first-line therapies for hypertension unless there are compelling indications for other drug classes. Diuretics and beta-blockers, however, may worsen dyslipidemia and glucose tolerance whereas antihypertensive agents in other drug classes may have neutral or beneficial effects. Initial clinical trials of antihypertensive regimens suggested that blood pressure lowering was the most important aspect of therapy and that the adverse effects on lipids and glucose tolerance did not impact clinical outcomes. Newer trials, however, question this finding and implicate these pleotropic effects as contributing to the results of the trials. Patients with cardiometabolic risk factors may have compelling indications for agents that inhibit the renin-angiotensin-aldosterone system, relegating diuretics and beta-blockers to third-line therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22037772     DOI: 10.1007/s11883-011-0214-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  65 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Metabolic safety of antihypertensive drugs: myth versus reality.

Authors:  Sameer Stas; Lama Appesh; James Sowers
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

3.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  BMJ       Date:  1989-04-29

4.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

5.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

Authors:  Christian Torp-Pedersen; Marco Metra; Andrew Charlesworth; Phillip Spark; Mary Ann Lukas; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Willem J Remme; Armin Scherhag
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

6.  Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

Authors:  B Hedblad; J Wikstrand; L Janzon; H Wedel; G Berglund
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 8.  Impact of carvedilol on the serum lipid profile.

Authors:  Randall P Sharp; Riaz Sirajuddin; Imran M Sharief
Journal:  Ann Pharmacother       Date:  2008-03-25       Impact factor: 3.154

9.  Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism.

Authors:  E Perez-Stable; P V Caralis
Journal:  Am Heart J       Date:  1983-07       Impact factor: 4.749

10.  Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension.

Authors:  R Harper; C N Ennis; B Sheridan; A B Atkinson; G D Johnston; P M Bell
Journal:  BMJ       Date:  1994-07-23
View more
  3 in total

1.  Anthropometric variables, physical activity and dietary intakes of patients with uric acid nephrolithiasis.

Authors:  Alberto Trinchieri; Emanuele Croppi; Giovanni Simonelli; Carmine Sciorio; Emanuele Montanari
Journal:  Urolithiasis       Date:  2019-04-29       Impact factor: 3.436

2.  The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.

Authors:  Zoltán Nádházi; Csaba András Dézsi
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

3.  Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study.

Authors:  Chao-Ying Miao; Xiao-Fei Ye; Wei Zhang; Li-Nong Ji; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-06       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.